Literature DB >> 9108440

Induction of p21 by the Wilms' tumor suppressor gene WT1.

C Englert1, S Maheswaran, A J Garvin, J Kreidberg, D A Haber.   

Abstract

WT1 encodes a zinc finger transcription factor that is expressed in the developing kidney and the inactivation of which leads to Wilms' tumor, a pediatric kidney cancer. We have recently shown that inducible expression of WT1 in osteosarcoma cells triggers programmed cell death, an effect that is associated with transcriptional repression of the endogenous epidermal growth factor receptor. We now show that WT1-mediated apoptosis is preceded by induction of the cyclin-dependent kinase inhibitor p21, associated with G1 phase arrest. This effect is only demonstrated by WT1 isoforms with an intact DNA binding domain, and it is associated with increased expression of endogenous p21 mRNA. WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression. In the kidney, p21 is expressed in differentiating glomerular podocytes along with WT1. We conclude that induction of p21 expression may contribute to WT1-dependent differentiation pathways in the kidney and potentially to the function of WT1 as a tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108440

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

2.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

Review 3.  Polycomb group proteins: navigators of lineage pathways led astray in cancer.

Authors:  Adrian P Bracken; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

4.  Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.

Authors:  S Maheswaran; C Englert; G Zheng; S B Lee; J Wong; D P Harkin; J Bean; R Ezzell; A J Garvin; R T McCluskey; J A DeCaprio; D A Haber
Journal:  Genes Dev       Date:  1998-04-15       Impact factor: 11.361

5.  Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1.

Authors:  D J Richard; V Schumacher; B Royer-Pokora; S G Roberts
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

6.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

7.  The Wilms' tumor gene Wt1 is required for normal development of the retina.

Authors:  Kay-Dietrich Wagner; Nicole Wagner; Valerie P I Vidal; Gunnar Schley; Dagmar Wilhelm; Andreas Schedl; Christoph Englert; Holger Scholz
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

8.  Modification of EWS/WT1 functional properties by phosphorylation.

Authors:  J Kim; J M Lee; P E Branton; J Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

9.  2-methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest.

Authors:  Avudaiappan Maran; Kristen L Shogren; Michaela Benedikt; Gobinda Sarkar; Russell T Turner; Michael J Yaszemski
Journal:  J Cell Biochem       Date:  2008-08-01       Impact factor: 4.429

10.  The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1.

Authors:  Dagmar Wilhelm; Christoph Englert
Journal:  Genes Dev       Date:  2002-07-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.